11 results about "Hypopigmentation" patented technology

The invention provides application of UBR5 in preparation of drugs for treating pigmented skin diseases, and further the pigmented skin diseases comprise various types of pigmented nevus (mainly congenital pigmented nevus and megalous with the risk of malignant transformation). Various pigmented spots (mainly chloasma, freckles, Taitian nevus, post-inflammation hyperpigmentation and the like) and hypopigmentation / depigmentation spots (mainly leucoderma, post-inflammation hypopigmentation and the like). Experimental results show that UBR5 is highly expressed in disease tissues such as pigmented nevus. The UBR5 expression level and the melanogenesis ability are in significant positive correlation, targeted knockout / knockdown of UBR5 in melanocytes can significantly inhibit the expression level of melanogenesis related genes such as MITF, TRP1, TRP2, TYR and other proteins, the melanin content of melanocytes and tyrosinase activity, vice versa, and the melanogenesis ability of melanocytes after overexpression of UBR5 is significantly increased.

The present application belongs to the technical field of traditional Chinese medicine composition, and relates to a traditional Chinese medicine transdermal external preparation for treating vulvar hypopigmentation disease. The preparation is a paste prepared by mixing traditional Chinese medicine powder and horse oil. The traditional Chinese medicine powder is composed of the following raw materials by weight: Xuchangqing 10-12, Pugongying 10-15, Difusiduo 12-15, Tuzifuding 12-15, Baiji 10-15, Huzhang 9-12, Quansie 6-10, Diyu 10-12, Xuezhi 10-12, Danggui 6-10, Rushang 6-10, Miedu 6-10, Bingpian 1-3. The traditional Chinese medicine transdermal external preparation has definite and significant effects on vulvar hypopigmentation disease, especially in relieving intractable pruritus, promoting pigment recovery and improving skin sclerosis / atrophy. The traditional Chinese medicine transdermal external preparation has high safety, few adverse reactions and low recurrence rate.

The peptides of the invention have a sequence with at least 85% of identity with a sequence SEQ ID NO: 1 or 2. These peptides regulate melanocyte activity in terms of proliferation and production of melanin. Therefore, they are useful in the treatment of melanomas but also of cosmetic cutaneous hyper or hypopigmentation.

Use of hydroxytyrosol or 3,4-dihydroxyphenylethanol-O-β-D-glucoside in promoting melanin generation. The effect of hydroxytyrosol or 3,4-dihydroxyphenylethanol-O-β-D-glucoside in the generation of melanin in recombinant human tyrosinase, mouse B16 cells, and AB-strain wild-type Danio rerio has been studied, and the results show that hydroxytyrosol or 3,4-dihydroxyphenylethanol-O-β-D-glucoside can promote the generation of melanin. Hydroxytyrosol or 3,4-dihydroxyphenylethanol-O-β-D-glucoside can be used for tanning, treating hypopigmentation diseases, blackening hair, and the like, to expand its pharmaceutical application.

The peptides of the invention have a sequence with at least 85% identity with a sequence SEQ ID NO: 1 or 2.These peptides regulate melanocyte activity in terms of proliferation and production of melanin. Therefore, they are useful in the treatment of melanomas but also of cosmetic cutaneous hyper or hypopigmentation.

The invention provides application of SLC16A10 in diagnosis and treatment of psoriasis, and relates to the technical field of biological medicines. The research of the inventor finds that SLC16A10 can participate in metabolism of arachidonic acid in keratinocytes by adjusting the homeostasis of thyroid hormones so as to promote the occurrence and development of psoriasis; the SLC16A10 represents a promising therapeutic target for treating psoriasis drip, and can improve the curative effect of the existing immune targeted therapeutic drug; comprehensive in-vitro and in-vivo experiments prove that the severity and excessive inflammation of psoriasis can be relieved by down-regulation of the SLC16A10; in addition, the SLC16A10 can induce one of sequelae of psoriasis, namely post-inflammation hypopigmentation, by inhibiting melanogenesis. Research results of the invention show that the SLC16A10 has potential as a psoriasis diagnosis biomarker and a treatment target.

The present invention relates to a composition for stimulating melanogenesis, comprising Cirsium japonicum extract as an effective ingredient. The composition has no skin irritation and cytotoxicity and is excellent in human stability and very effective in stimulating melanogenesis. Therefore, the composition can be safely used in cosmetic or pharmaceutical composition for preventing, improving or treating vitiligo, white hair or hypopigmentation.

The invention belongs to the technical field of traditional Chinese medicine compositions, and relates to a traditional Chinese medicine transdermal external preparation for treating vulva hypopigmentation diseases. The traditional Chinese medicine powder is prepared from the following raw materials in parts by weight: 10 to 12 parts of radix cynanchi paniculati, 10 to 15 parts of herba taraxaci, 12 to 15 parts of fructus kochiae, 12 to 15 parts of rhizoma smilacis glabrae, 10 to 15 parts of rhizoma bletillae, 9 to 12 parts of rhizoma polygoni cuspidati, 6 to 10 parts of scorpion, 10 to 12 parts of radix sanguisorbae, 10 to 12 parts of dragon's blood, 6 to 10 parts of radix angelicae sinensis, 6 to 10 parts of frankincense, 6 to 10 parts of myrrh and 1 to 3 parts of borneol. The traditional Chinese medicine transdermal external preparation has an exact and remarkable curative effect on vulva hypopigmentation diseases, particularly has outstanding advantages in the aspects of relieving intractable itching, promoting pigment recovery and improving skin sclerosis / atrophy, and is high in safety, few in adverse reaction and low in recurrence rate.

The application provides application of UBR5 in preparation of a drug for treating pigmented skin diseases, and further the pigmented skin diseases include various types of pigmented nevus (mainly congenital pigmented nevus and giant nevus with the risk of malignant transformation), various pigmented spots (mainly chloasma, freckle, nevus spilus, post-inflammatory pigmentation and the like) and hypopigmentation / loss of pigmentation spots (mainly vitiligo, post-inflammatory hypopigmentation and the like). The experimental results of the application show that UBR5 is highly expressed in the tissues of diseases such as pigmented nevus. The expression level of UBR5 is significantly positively correlated with the melanogenesis capacity, the expression level of proteins such as MITF, TRP1, TRP2 and TYR related to melanogenesis is significantly inhibited by targeted knockout / knockdown of UBR5 in melanocytes, the melanin content and tyrosinase activity of the melanocytes, and vice versa, the melanogenesis capacity of the melanocytes is significantly increased after overexpression of UBR5.

The application provides application of SLC1A4 in preparation of a medicament for treating a pigmentation abnormality skin disease, specifically, application of a reagent for detecting SLC1A4 as a detection reagent or a detection reagent kit for detecting a pigmentation abnormality skin disease, and application of an enhancer or inhibitor targeting SLC1A4 in preparation of a medicament for treating a pigmentation abnormality skin disease. The enhancer targeting SLC1A4 is a SLC1A4 overexpression plasmid, and the inhibitor targeting SLC1A4 is an SLC1A4 siRNA or shRNA. The pigmentation abnormality skin disease includes a hyperpigmentation skin disease and a hypopigmentation skin disease.

Provided herein are methods, uses, and pharmaceutical compositions of antibodies that bind human IL-13 ("anti-IL-13 antibodies") for treating post-inflammatory hyperpigmentation or hypopigmentation of skin, e.g., post-inflammatory hyperpigmentation or hypopigmentation of skin associated with atopic dermatitis.